Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

(2021) Xuewu Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

(2021) Wenzhong Yan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer

(2020) Shipeng He et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy

(2020) Tingting Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors

(2020) Amr K.A. Bass et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

(2020) Jinfeng Zhang et al.   Pharmaceuticals

Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity

(2019) Yahui Huang et al.   Acta Pharmaceutica Sinica B

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

(2018) Robert D. Leone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

(2018) Jie Zang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer

(2018) Yongtao Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer

(2018) Heba M. Hesham et al.   MEDICINAL RESEARCH REVIEWS

Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals

(2018) Prakash Rucktooa et al.   Scientific Reports

Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents

(2018) Shipeng He et al.   JOURNAL OF MEDICINAL CHEMISTRY

Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

(2018) Yepeng Luan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer

(2017) Mohammad H. Kazemi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery

(2017) Wei Chen et al.   ACS Medicinal Chemistry Letters

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents

(2014) Jianjun Cheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update

(2011) B. B. Fredholm et al.   PHARMACOLOGICAL REVIEWS

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines

(2008) Roger J. Gillespie et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS